A Phase I Open-label Study of Selinexor with Paclitaxel and Carboplatin in Patients with Advanced Ovarian or Endometrial Cancers

PURPOSE: Selinexor, a selective inhibitor of nuclear export, monotherapy causes nuclear accumulation of tumor-suppressor proteins and has anti-tumor activity in ovarian and endometrial cancers. The safety and tolerability of oral selinexor plus intravenous carboplatin and paclitaxel chemotherapy (se...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Gynecol Oncol
Autori principali: Rubinstein, Maria M., Grisham, Rachel N., Cadoo, Karen, Kyi, Chrisann, Tew, William P., Friedman, Claire F., O’Cearbhaill, Roisin E., Zamarin, Dmitriy, Zhou, Qin, Iasonos, Alexia, Nikolovski, Ines, Xu, Hongmei, Soldan, Krysten N., Caird, Imogen, Martin, Madhuri, Guillen, Joyce, Eid, Khalil T., Aghajanian, Carol, Makker, Vicky
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2020
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7779742/
https://ncbi.nlm.nih.gov/pubmed/33139041
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2020.10.019
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi